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Recommendations for the management of Acanthamoeba keratitis
Acanthamoeba is the causative agent of a
painful, sight-threatening keratitis. The
first case of Acanthamoeba keratitis was
reported in 1972 in the USA and soon
after, it was reported in the UK in 1974
(Nagington et al., 1974). Ulcerative
keratitis due to Acanthamoeba is often
associated with the improper use of
contact lenses, but it is also reported in
non-contact lens wearers (Sharma et al.,
2000). At present, treatment involves
hourly topical application of a mixture of
anti-Acanthamoeba drugs including 0.02%
polyhexamethylene biguanide or
chlorhexidine for up to a week. The hourly
drops may be reduced after 48 h to
alleviate the epithelial toxicity, but
treatment continues for up to a year
(Clarke et al., 2012).
In a recent report by Agahan et al. (2009),
it was demonstrated that three patients
with Acanthamoeba keratitis were treated
successfully without any anti-
Acanthamoeba drugs. The patients had no
history of contact lens wear and were
admitted due to intolerable eye pain and
blurring of vision. Ocular examination
revealed corneal ulceration and stromal
infiltrates. The patients were reportedly
diagnosed with Acanthamoeba keratitis
(Agahan et al., 2009). All patients were
treated for photophobia with
anticholinergics (atropine). In
ophthalmologic practice, atropine is
commonly used for ciliary muscle
paralysis to block accommodation and to
prevent reflex constriction of pupillary
muscle. For inflammation and pain, the
patients were given topical diclofenac
sodium (0.1%) every hour for up to a
week. The patients responded well to this
combination. Based on this, it was
suggested that the successful prognosis
was due to suppression of the
inflammation. Subsequently, the
treatment was continued for up to 3
months, with one case receiving it for up
to 10 months. As the patients were
recovering well, no anti-Acanthamoeba
agents were introduced. No corneal melt
or rupture was observed and no
recurrence was seen for at least 12 months
of the follow-up (Agahan et al., 2009). In
another case of Acanthamoeba keratitis,
atropine eye drops added to conventional
anti-Acanthamoeba agents with oral
diclofenac and steroids restored the vision
(Stapleton et al., 2009).
The aim of this letter is to provide the
scientific basis of the successful prognosis
observed in these patients in the absence of
anti-Acanthamoeba agents. Notably, recent
studies have shown potent anti-
Acanthamoeba effects of the
anticholinergic agent procyclidine in vitro
(Baig et al., 2013). Procyclidine is generally
given in less advanced forms of
Parkinson’s disease. It is believed to act by
reducing the effects of acetylcholine
(Sweeney, 1995; Olanow & Koller, 1998).
Based on this, we hypothesize that the
successful prognosis observed in the above
Acanthamoeba keratitis cases were not
merely due to regulation of the
inflammatory process, but were most likely
due to the anti-muscarinic effects of
atropine, leading to killing of the
Acanthamoeba. In support of this notion,
we report here that atropine acts as an
anti-Acanthamoeba agent. Briefly, amoebae
(56105) were incubated with 200 mg
atropine ml21 and cytotoxicity was
determined by adding 0.1% trypan blue
and enumerating the number of live (non-
stained) and dead (stained) Acanthamoeba
castellanii using a haemocytometer. The
counts from A. castellanii incubated with
PBS alone were used as controls. The
results revealed that atropine produced a
kill rate greater than 55±4.5%. The data
are representative of at least three
independent experiments and expressed as
mean±SE.
Among five muscarinic receptors targeted
by atropine, we further determined the
receptor subtype involved in atropine-
mediated A. castellanii death. The use of
dicyclomine, which selectively targets the
M1 receptor, resulted in more than 75%
parasite killing within 8 h at a
concentration of 90 mM. Agents targeting
the M1 receptor thus should prove highly
effective in the treatment of this blinding
infection.
Additionally, we propose amlodipine as a
substitute anti-inflammatory agent
(Kataoka et al., 2004) for diclofenac
sodium eye drops. The anti-inflammatory
effects of amlodipine are probably
mediated by the inhibition of monocyte
chemokine protein-1, tumour growth
factor-1, the Rho pathway and oxidative
stress (Kataoka et al., 2004). Moreover, our
recent findings showed potent amoebicidal
properties of amlodipine (Baig et al.,
2013), and thus its use is likely to lead to
dual effects in the successful management
of Acanthamoeba keratitis.
In conclusion, we suggest the use of the
selective muscarinic antagonist
dicyclomine rather than atropine, as well
as topical amlodipine to substitute for
diclofenac sodium in cases of
Acanthamoeba keratitis. The proposed use
of these drugs needs to be tested in clinical
trials to prove their efficacy in amoebic
keratitis.
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